Stopping Rebif (Interferon Beta-1a) in MS: Risks and Guidance

Discontinuing Rebif (IFN β-1a) increases relapse risk and may accelerate disability progression in relapsing-remitting MS.

Mechanism

Rebif modulates immune response: ↓ pro-inflammatory cytokines, ↓ MHC expression, ↓ T-cell migration across BBB. Stopping removes this suppression → immune reactivation.

Consequences of Stopping

  • Rebound relapse: Often more severe than pre-treatment baseline; can occur within weeks.
  • MRI activity: New/enlarging T2/Gd+ lesions.
  • Disability worsening: Incomplete recovery from rebound attacks → stepwise accumulation.
  • Loss of "therapeutic lag" benefit: Prior treatment effect wanes.

If Discontinuation Is Necessary

  • Never stop abruptly. Taper over 4–12 weeks per neurologist.
  • Switch therapy: Start new DMT (e.g., fingolimod, natalizumab, ocrelizumab, cladribine) with overlap/washout per protocol.
  • Monitor: Clinical q3–6mo; MRI q6–12mo for 1–2 years.
  • Pregnancy: Discuss pre-conception; some DMTs continued, others stopped with restart plan.

Shared Decision-Making

Weigh side effects (flu-like, injection site, liver, depression, cytopenias) vs. relapse risk. Many patients tolerate long-term; others switch for efficacy/tolerability. No "drug holiday" without replacement.

Prescription Medications - Related Articles